September 10, 2007

Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Society's 29th Annual Meeting

WEST BRIDGEWATER, Mass., Sept. 10 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that data highlighting the advantages of pressure cycling technology (PCT) in studies to (1) better understand the events surrounding stroke, (2) detect biomarkers of colon cancer, and (3) detect proteins associated with embryo viability are to be presented this week in three presentations at the 29th Annual Meeting of the British Mass Spectrometry Society (BMSS). The data were generated by scientists at The New York University (NYU) School of Medicine and the Brooklyn Hospital Center. The presentations will be delivered by Dr. Paul Pevsner, M.D. of the NYU School of Medicine.

Approximately three hundred scientists from around the world are expected to attend the BMSS meeting, where mass spectrometry-related data generated in many key areas of human, animal, and plant research will be showcased. The meeting is being held at the Heriot-Watt University in Edinburgh Scotland.

Dr. Paul H. Pevsner, senior author of the research studies and a scientific investigator at the NYU School of Medicine, said: "Our research program is focused in three areas. First, we are investigating the cascade of events that occurs immediately following a stroke, in an effort to develop successful post-stroke therapeutics. Second, we are attempting to discover new biomarkers of colon cancer, in an effort to develop better surgical aids and diagnostics. Third, we are trying to identify proteins associated with embryo viability from growth media fluid, in an effort to develop better in- vitro fertilization techniques."

Dr. Pevsner continued: "In all cases, we were extremely pleased that PCT could successfully extract the bio-materials of interest, and with a level of speed, reproducibility, and ease-of-use that we have here-to-fore been unable to achieve with any existing extraction method tried. We believe that PCT was essential to our ability to generate the data that we are presenting at the BMSS meeting, and we have therefore made PCT our sample preparation method of choice going forward."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater)

to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the use of the PCT SPS by the NYU School of Medicine and the Brooklyn Hospital Center, the results of their studies to be presented at the British Mass Spectrometry Society's 29th Annual Meeting, and the advantages of PCT over other sample preparation methods. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that other laboratories may be unable to duplicate the results generated by Dr. Pevsner and his colleagues; the possibility that the data generated may not be beneficial in the development of new therapeutics and diagnostics for stroke, colon cancer, and embryo viability; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Senior Vice President of Finance & CFO
Pressure BioSciences, Inc.
(508) 580-1818 (T)

SOURCE Pressure BioSciences, Inc.